Arsenic trioxide is under clinical development by Syros Pharmaceuticals and currently in Phase I for Acute Promyelocytic Leukemia. According to GlobalData, Phase I drugs for Acute Promyelocytic Leukemia have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Arsenic trioxide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Arsenic trioxide overview

Arsenic trioxide is under development for the treatment of relapsed and refractory acute myelocytic leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), mantle cell lymphoma (MCL) and myeloproliferative neoplasm. It is administered orally. The drug candidate acts by preventing the production of DNA, which is necessary for leukaemia cells to grow.

See Also:

Syros Pharmaceuticals overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Syros Pharmaceuticals (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist, SY-2101, a arsenic trioxide (ATO) and SY-5609, a highly selective and potent oral inhibitor. Syors products are used to treat the patients with acute myeloid leukemia and myelodysplastic syndrome (MDS); acute promyelocytic leukemia, pancreatic cancer and BRAF-mutant colorectal cancer. It offers services such as gene regulation, research and drug development, drug discovery, clinical trials among others. Syros is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Arsenic trioxide’s drug-specific PTSR and LoA scores, buy the report here.